News Column

Findings from University of Alabama Broadens Understanding of Squamous Cell Carcinoma (A novel extracellular drug conjugate significantly inhibits...

July 16, 2014



Findings from University of Alabama Broadens Understanding of Squamous Cell Carcinoma (A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma)

By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Oncology have been presented. According to news originating from Birmingham, Alabama, by NewsRx correspondents, research stated, "Despite advances in treatment modalities, head and neck squamous cell carcinoma (HNSCC) remains a challenge to treat with poor survival and high morbidity, necessitating a therapy with greater efficacy. EDC22 is an extracellular drug conjugate of the monoclonal antibody targeting CD147 (glycoprotein highly expressed on HNSCC cells) linked with a small drug molecule inhibitor of Na, K-ATPase."

Our news journalists obtained a quote from the research from the University of Alabama, "In this study, EDC22's potential as a treatment modality for HNSCC was performed. HNSCC cell lines (FADU, OSC-19, Cal27, SCC-1) were cultured in vitro and proliferation and cell viability were assessed following treatment with a range of concentrations of EDC22 (0.25-5.00?g/mL). Mice bearing HNSCC xenografts (OSC-19, SCC-1) were treated with either EDC22 (3-10mg/kg), anti-CD147 monoclonal antibody, cisplatin (1mg/kg) or radiation therapy (2Gy/week) monotherapy or in combination. In vitro, treatment with minimal concentration of EDC22 (0.25?g/mL) significantly decreased cellular proliferation and cell viability (p

According to the news editors, the research concluded: "EDC22 is a potent inhibitor of HNSCC cell proliferation in vitro and in vivo, warranting further investigations of its clinical potential in the treatment of HNSCC."

For more information on this research see: A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma. Oral Oncology, 2013;49(10):991-7. Oral Oncology can be contacted at: Pergamon-Elsevier Science LTD, the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. (Elsevier - www.elsevier.com; Oral Oncology - www.elsevier.com/wps/product/cws_home/105)

The news correspondents report that additional information may be obtained from L. Sweeny, University of Alabama at Birmingham, Dept. of Surgery, Division of Otolaryngology - Head and Neck Surgery, 1670 University Boulevard, Volker Hall G082, Birmingham, AL 35233, United States. Additional authors for this research include Y.E. Hartman, K.R. Zinn, J.R. Prudent, D.J. Marshall, M.S. Shekhani and E.L Rosenthal (see also Oncology).

The publisher's contact information for the journal Oral Oncology is: Pergamon-Elsevier Science LTD, the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England.

Keywords for this news article include: Alabama, Therapy, Oncology, Birmingham, United States, Head and Neck Cancer, Squamous Cell Carcinoma, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters